Protein kinase C targeting in antineoplastic treatment strategies

Investigational New Drugs

Volumn 17, Issue 3, 1999, Pages 227-240

  Jarvis, W David ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4' N benzoyl staurosporine (CGP 41251); 7 Hydroxy staurosporine (UCN 01); Apoptosis; Bryostatin 1; Calphostin C (UCN 1028c); Diglyceride; Protein kinase C; Safingol; Sphingoid bases; Staurosporine

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CALPHOSTIN C; CYTARABINE; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; SAFINGOL;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CYTOPROTECTION; ENZYME INHIBITORS; HUMANS; LACTONES; MACROLIDES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NAPHTHALENES; PROTEIN KINASE C; SPHINGOSINE; STAUROSPORINE;

EID: 0033386539     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006328303451     Document Type: Review

References (164)

1. Mellor H, Parker PJ: The extended protein kinase C super-family. Biochem J 332: 281-292, 1998
2. Gescher A, Dale IC: Protein kinase C: a novel target in rational drug design. Anticancer Drug Res 4: 93-105, 1989
3. Weinstein IB: Protein kinase C: implications for cancer prevention and treatment. Mt Sinai J Med 59: 387-393, 1992
4. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257-280, 1993
5. Ward NE, Gravitt KR, Fan D: The role of protein kinase C in multidrug resistance. Cancer Treatment Res 73: 41-55, 1994
6. Philip PA, Harris AL: Potential for protein kinase C inhibitors in cancer therapy. Cancer Treatment Res 78: 3-27, 1995
7. Grant S, Jarvis WD: Modulation of drug-induced apoptosis by interruption of protein kinase C-dependent signaling pathways: evolution of a new chemotherapeutic strategy. Clin Cancer Res 2: 1915-1920, 1996
8. Deacon EM, Pongracz J, Griffiths G, Lord JM: Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 50: 124-131, 1997
9. Spiegel S, Merrill AH: Sphinogolipid metabolism and cell growth regulation. FASEB J 10: 1388-1397, 1996
10. Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Annu Rev Physiol 60: 643-665,1998
11. Jarvis WD, Grant S: The role of ceramide in the apoptotic response to antineoplastic agents. Curr Op Oncol 10: 552-559, 1998
12. Perry DK, Hannun YA: The role of ceramide in cell signaling. Biochim Biophys Acta 1436: 233-243, 1998
13. Hannun YA, Bell RM: Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 235: 670-674, 1987
14. Hannun YA, Bell RM: Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243: 500-507, 1989
15. Hannun YA, Bell RM: Regulation of protein kinase C by sphingosine and lysosphingolipids. Clin Chem Acta 185: 333-345, 1989
16. Merrill AH, Nimkar S, Menaldino D, Hannun YA, Loomis SC, Bell RM, Tyagi SR, Lambeth JD, Stevens VL, Hunter R: Structural requirements for long-chain (sphingoid) inhibition of protein kinase C in the cellular effects of these compounds. Biochemistry 28: 3138-3145, 1989
17. Hannun YA: Sphingolipid messengers as tumor-suppressor lipids. Adv Exp Med Biol 400A: 305-312, 1997
18. Merrill AH, Nimkar S, Stevens VL, Jamison KK, Liotta DC: Characteristics of the growth-inhibition and cytotoxicity and long-chain (sphingoid) bases: evidence for an involvement of protein kinase C. Biochem Biophys Acta 1051: 37-45, 1990
19. Sadahira Y, Ruan F, Nakamori S-I, Igarashi Y: Sphingosine-1-phosphate, a specific endogenous signaling molecule controlling tumor cell growth and invasiveness. Proc Natl Acad Sci (USA) 89: 9686-9690, 1992
20. Merrill AH, Serenit A, Stevens VL, Hannun YA, Bell RM, Kincade JM: Inhibition of phorbol ester-dependent differentiation of human promyelocytic HL-60 cells sphinganine and other long-chain bases. J Biol Chem 261: 12610-12615, 1986
21. Campbell PI: Toxicity of some charged lipids used in liposome preparations. Cytobios 37: 21-26, 1983
22. Parenteau H, Ho T-F, Eckel LA, Carroll KK: Effects of a long-chain fatty amine on mammary carcinogenesis. Nutr Cancer 17: 235-241, 1992
23. Ohta H, Yatomi Y, Sweeney EA, Hakomori S-I, Igarashi Y: A possible role for sphingosine in induction of apoptosis by tumor necrosis factor in human neutrophils. FEBS Lett 355: 267-270, 1994
24. Ohta H, Sweeney EA, Masamune A, Yatomi Y, Hakomori S-I, Igarashi Y: Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res 55: 691-697, 1995
25. Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S: Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 271: 8275-8284, 1996
26. Jarvis WD, Fornari FA, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Auer KL, Dent P, Grant S: Coordinate regulation of stress-activated protein kinase and mitogen-activated protein kinase cascades in the apoptotic actions of ceramide and sphingosine in human myeloid leukemia cells. Mol Pharmacol 52: 935-947, 1997
27. Jones MJ, Murray AW: Evidence that ceramide selectivity inhibits protein kinase C-α translocation. J Biol Chem 270: 5007-5013, 1995
28. Lee JY, Hannun YA: Ceramide inactivates cellular cPKCα. J Biol Chem 271: 13169-13174, 1996
29. Abe A, Wu D, Shayman JA, Radin NS: Metabolic effects of short-chain ceramides and sphingolipids on protein kinase C. Eur J Biochem 210: 765-773, 1992
30. Dobrowsky RT, Hannun YA: Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267: 5048-5051, 1992
31. 2. J Biol Chem 268: 15523-15530, 1993
32. Hannun YA, Obeid LM, Wolff RA: The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv Lipid Res 25: 43-64, 1995
33. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274: 1855-1899, 1996
34. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S: Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci (USA) 91: 73-77, 1994
35. Jarvis WD, Fornari FA, Browning JL, Gewirtz DA, Kolesnick RN, Grant S: Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 269: 31658-31692, 1994
36. Porn-Ares MT, Chow SC, Slotte JP, Orrenius S: Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells. Exp Cell Res 235: 48-54, 1997
37. Mayne GL, Murray AW: Evidence that PKC mediates inhibition of TNF-induced apoptosis in U937 histoicytic lymphoma cells. J Biol Chem 273: 24115-24121, 1998
38. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaels J, Vlodansky F, Fuks Z: PKC mediates basic fibroblastic growth factor protection of endothelial against ionizing radiation. Cancer Res 54: 2591-2597, 1994
39. Fuks Z, Haimovitz-Friedman A, Kolesnick RN: The role of the sphingomyelin pathway and protein kinase C in radiation-induced cell killing. Important Adv Oncol 5: 19-31, 1995
40. Kobayashi E, Nakano H, Morimoto M, Tamaoki T: Calphstin C (UCN-1028c), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548553, 1989
41. Tamaoki T, Takahashi I, Kobayashi E, Nakano H, Akinaga S, Susuki K: Calphostin C (UCN-1029c) and calphostin-related compounds, a new class of specific and potent inhibitors of protein kinase C. Adv Second Messenger and Phosphoprotein Res 24: 297-401, 1990
42. Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732-735, 1990
43. Tamaoki T: Use and specificity of staurosporine, UCN-01, and calcphostin C as protein kinase inhibitors. Methods Enzymol 201: 340-347, 1994
44. Herbert JM, Augereau JM, Gleye J, Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172: 993-999, 1990
45. Bertrand R, Solary E, O'Conner P, Kohn KW, Pommier Y: Induction of a common pathway for apoptosis by staurosporine. Exp Cell Res 211: 314-321, 1994
46. Solary E, Betrand R, Kohn KW, Pommier Y: Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerases I and II inhibitors. Blood 81: 1359-1368, 1993
47. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemic cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707-1714, 1994
48. Ikeda K, Kajiwara K, Tanabe E, Takamura S, Kishida E, Masuzawa Y, Kojo S: Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis in HL-60 cells. Biochem Pharmacol 57: 1361-1365, 1999
49. Byung-Chung S, Se-Young C, Jang-Soo C, Kyong-Tai K: Opposing regulatory effects of PKC on the cAMP cascade in HL60 human promyelocytic leukemia cells. Eur J Pharmacol 353: 105-115, 1998
50. Thorp KM, Southern L, Matthews N: Effect of serine/threonine kinase inhibitors on human lymphocytes and U937 cells. Immunology 81: 546-550, 1994
51. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z: The cell cycle-related difference in susceptibility of HL-60 cells to apoptosis is induced by various antineoplastic agents. Cancer Res 53: 3186-3192, 1994
52. Rajewski RA, Kosednar DG, Matches TA, Wong OS, Borchett K, Thakker K: Stereospecific analysis of a novel protein kinase C inhibitor. J Pharm Biomed Anal 13: 247-253, 1995
53. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD, Susick RL: Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 25: 201-207, 1995
54. Schwartz GK, Juang J, Kelsen D, Albino AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85: 402-407, 1993
55. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F, Kelsen DP, Fuks Z, Albino AP: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 87: 1394-1399, 1995
56. Jarvis WD, Fornari FA, Tombes RB, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S: Direct evidence for involvement of mitogen-activated protein kinase (MAPK), rather than stress-activated protein kinase (SAPK), in potentiation of 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 54: 844-856, 1998
57. Grant S: Biochemical modulation of cytosine arabinoside. Pharmac Ther 48: 29-44, 1990
58. Grant S: 1-[β-D-arabinofuranosyl]cytosine: molecular and cellular pharmacology. Adv Cancer Res 72: 197-233, 1997
59. Kucera GL, Capizzi RL: 1-[β-D-arabinofuranosyl]cytosine-diphosphate is formed by reversal of cholinephosphotransferase and not via cytidylyltransferase. Cancer Res 52: 3886-3891, 1992
60. Strum JL, Small GW, Pauig SB, Daniel LW: 1-[β-D-arabinofuranosyl]cytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 269: 15493-15497, 1994
61. Kharbanda SM, Datta R, Kufe DW: Regulation of c-jun expression in HL-60 leukemia cells by 1-[β-D-arabinofuranosyl]cytosine; potential involvement of a protein kinase C mechanism. Biochemistry 30: 7747-7752, 1991
62. Kharbanda SM, Emoto Y, Kiasaki H, Saleem A, Kufe DW: 1-[β-D-arabinofuranosyl]cytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol diesterresistant myeloid leukemia cells. Mol Pharmacol 46: 67-72, 1994
63. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S: Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 838-852, 1994c
64. Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD: Modulation of 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncology Res 6: 87-99, 1994
65. Auzenne E, Leroux E, Hu M, Pollock RE, Feig B, Klostergaard J: Cytotoxicity of sphingolipids as single- or multi-modality agents in human melanoma cells. Melanoma Res 8: 227-239, 1998
66. Klostergaard J, Auzenne E, Leroux E: Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells. Leuk Res 22: 1049-1056, 1998
67. Fine RL, Chambers TC: P-glycoprotein, multidrug resistance, and protein kinase C. Stemm Cells 14: 47-55m, 1996
68. Sachs CW, Safa AR, Harrison SD, Fine RL: Partial inhibition of multidrug-resistance by safingol os independent of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639-26648, 1995
69. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita T: Staurosporine, a potent inhibitor of phospholipid/calcium-dependent kinases. Biochim Biophys Res Commun 135: 397-402, 1986
70. Ruegg UT, Burgess GM: Staurosporine, K-252, and UCN-01: potent and non-specific inhibitors of protein kinases. Trends Pharmacol Sci 10: 218-220, 1989
71. Plumas J, Jacob MC, Chaperot L, Moleus JP, Sotta JJ, Benson JC: Tumor B-cells from non-Hodgkins lymphoma are resistant to CD95 (Fas/APO1)-mediated apoptosis. Blood 91: 2875-2885, 1998
72. Qiao L, Koustos M, Tsai LL, Kozoni V, Guzman J, Shiff SJ, Rigas B: Staurosporine inhibits proliferation, alters cell cycle distribution, and induced apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 107: 83-89, 1996
73. Shirohawa T, Sakakura C, Sewwney EA, Ozawa M, Takemoto M, Nishizawa K, Ohi Y, Igarashi Y: Sphingosine induces apoptosis in androgen-dependent human prostatic carcinoma DU-145 cells. FEBS Lett 407: 87-100, 1997
74. Abiko Y, Arai J, Mitamura J, Kaku T: Alteration of protooncogenes during apoptosis in the squamous cell carcinoma cell line SAS induced by staurosporine. Cancer Lett 118: 101-107, 1997
75. Boix J, Liecke N, Guste VJ, Comella JX: Characterization of the cell death process induced by staurosporine in human neuroblastoma cells. Neuropharmacol 36: 811-821, 1997
76. Janss AJ, Levow C, Bernhard EJ, Muschel RJ, McKenna WG, Sutton L, Phillips PC: Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines. Exp Cell Res 243: 29-38, 1998
77. Couldwell WT, Hinton DR, Hu S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994
78. Kobayashi D, Watanabe N, Yamauchi N, Tsei N, Sato T, Sasaki H, Okamoto T, Nitsu Y: Protein kinase C inhibitors augment TNF-induced apoptosis in normal human diploid cells. Chemotherapy 43: 415-423, 1997
79. Bertrand R, Solary E, O'Conner P, Kohn KW, Pommier Y: Induction of a common pathway for apoptosis by staurosporine. Exp Cell Res 211: 314-321, 1994
80. Lock RB, Thompson BS, Sullivan DM, Stribinskiene L: Potentiation of etoposide-induced apoptosis by human tumor cells is associated with events downstream of DNA-drug complex formation. Cancer Chemother Pharmacol 39: 399-409, 1997
81. Takahashi I, Kobayashi E, Asano K, Yoshida M: UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot 40: 1782-1784, 1987
82. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. Purification, physico-chemical properties, structural determination and biologic activities. J Antibiot 42: 571-576, 1989
83. Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732-735, 1990
84. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888-4892, 1991
85. Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S: Differing effects of staurosporine and UCN-01 on Rb phosphorylation and expression of lung cancer cell lines. Oncology 53: 494-504, 1996
86. Shao R-G, Cao C-X, Pommier Y: Activation of PKCα downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells. J Biol Chem 50: 31321-31325, 1997
87. Wang Q, Worland PJ, Clark JL, Carlson BA, Sauseville EA: Apoptosis in 7-hydroxystaurosporine-treated T-lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6: 927-936, 1995
88. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21-Cip1/Waf1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57: 1495-1501, 1997
89. Bunch RT, Eastman A: 7-hydrostaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese Hamster Ovary cells. Cell Growth Differ 8: 779-788, 1997
90. Akinaga S, Nomura K, Gomi K, Okabe M: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32: 183-189, 1993
91. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2: 791-797, 1996
92. Shao R-G, Cao C-X, Shimizu T, O'Connor PM, Kohn KW, Pommier Y: Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res 57: 4029-4035, 1997
93. Wang S, Vrana JA, Bartimole T, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S: Agents that downregulate or inhibit kinase C circumvent resistance to 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2. Mol Pharmacol 52: 1000-1009, 1997
94. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM: UCN-01: apotent abrogator of G2 checkpoint functionin cancer cells with disrupted p53. J Natl Cancer Inst 88: 956-965, 1996
95. 2 arrest through a Cdc2-dependent pathway that is associated with inactivated of the Wee1Hu kinase and activation of Cdc25C phosphatase. J Biol Chem 273: 38455-44464, 1998
96. 1-acid glycoprotein. Cancer Res 58: 3248-3255, 1998
97. 1-acid glycoprotein in humans. Cancer Res 59: 1054-1060, 1999
98. Meyer T, Regenass U, Fabbro D, Altari E, Rosal J, Muller M, Caravatti G, Matter A: A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Eur J Cancer 43: 851-856, 1989
99. Ikegami Y, Yano S, Nakao K: Antitumor effect of CGP-41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol 70: 65-72, 1996
100. Harkin ST, Cohen GM, Gescher A: Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol Pharmacol 54: 663-670, 1998
101. Gescher A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 31: 721-728, 1998
102. Zhang W, Dziak RM, Aletta JM: EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteblastic cells. J Cell Physiol 162: 348-358, 1995
103. Spinedi A, Oliverio S, DiSano F, Piacentini M: Calpain involvement in calphostin-induced apoptosis. Biochem Pharmacol 56: 1489-1592, 1998
104. Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM: Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin Cancer Res 4: 2967-2976, 1998
105. Leszczynski D: Regulation of cell cycle and apoptosis by protein kinase C in rat myeloid leukemia cells. Oncol Res 7: 471-479, 1995
106. Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific inhibitor of protein kinase C. J Neurosurg 83: 1008-1016, 1995
107. Weinstein IB, Begemann M, Zhou P, Han EK, Sgambuto A, Doki Y, Arber N, Ciapparone M, Yamamoto H: Disorders in cell circuitry associated with multistage carcinogenesis: explotable targets for cancer prevention and chemotherapy. Clin Cancer Res 3: 2696-2702, 1997
108. Begemann M, Kashimawo SA, Lunn RM, Delohery T, Choi J, Kine S, Heitjani DF, Santella RM, Schiff PB, Bruce NJ, Weinstein IB: Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Anticancer Res 18: 3139-3152, 1998
109. Minara MD, Felipo V, Grisola S: Differential effects of the protein kinase C inhibitors H7 and calphostin C on the cell cycle. Brain Res 596: 157-162, 1992
110. Pollack IF, Kawecki S: The effect of calphostin C, a potent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J Neurooncol 31: 255-266, 1997
111. 2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death. J Biol Chem 274: 5310-5317, 1999
112. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW: Activated calphostin C cytotoxicty is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4: 2391-2398, 1998
113. Diwa Z, Lown JW: Photosensitization with anticancer agents: EPR studies of photodynamic activation of calphostin C. Free Radical Biol Med 16: 645-652, 1994
114. Murata M, Nagai M, Fijita M, Ohmori M, Takehara J: Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated BCL2. Cell Mol Life Sci 53: 737-743, 1997
115. Weller M, Trepel M, Grimmel C, Schabet M, Brememn D, Krajewski S, Reed JC: Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of BCL2 expression, and does not require wild type p53. Neurol Res 19: 459-470, 1997
116. Gupta S, Patel K, Singh H, Gollapudi S: Effect of calphostin C on daunorubicin resistance in P388/ADR cells and HL-60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 76: 139-145, 1994
117. Findik D, Song Q, Hidaka H, Lavin M: Protein kinase A inhibitors enhance radiation-induced apoptosis. J Cell Biochem 57: 12-21, 1995
118. Pettit GR, Herald CL, Boubek DL, Herald DL, Arnold E, Clardy J: Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846-6948, 1982
119. Hess AD, Silankis MK, Esa AH, Pettit GR, May WS: Activation of human T lymphocytes by bryostatin 1. J Immunol 141: 3263-3269, 1988
120. Kennedy MJ, Prestigiacomo LJ, Tylor G, May WS, Davidson NE: Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52: 1278-1283, 1992
121. Dale IL, Gescher A: Effects of activators of protein kinase C, including bryostatin 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158-163, 1989
122. Schucter LM, Esa AH, May WS, Laulis MK, Pettit GR, Hess AD: Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51: 682-687, 1991
123. Berkow RL, Kraft AS: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Biochem Biophys Res Commun 131: 1109-1116, 1985
124. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores RA, Yuspa SH: Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol ester in SENCAR mouse skin. Carcinogenesis 8: 1343-1346, 1987
125. Kraft AS, Smith JB, Berkow RL: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci (USA) 83: 1334-1338, 1986
126. 2+-sensitive, phospholipid-dependent kinase activity in phorbol ester-treated 3T3 cells. Biochem Biophys Res Commun 120: 1053-1059, 1984
127. Szallasi Z, Smith CB, Pettit GR, Blumberg PM: Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem 269: 2118-2124, 1994
128. II-protein kinase C to the nucleus of human promyelocytic leukemia (HL-60) cells. J Biol Chem 266: 28-33, 1991
129. Isakov N, Galron D, Mustelin T, Pettit GR, Altman A: Inhibition of phorbol ester-induced T cell proliferation by bryostatin 1 is associated with rapid degradation of protein kinase C. J Immunol 150: 1195-1204, 1993
130. Lee H-W, Smith L, Pettit GR, Vinitsky A, Smith JB: Ubiquitinization of protein kinase C-α and degradation by the proteosome. J Biol Chem 271: 20973-20976, 1996
131. May WS, Sharkis SS, Esa AH, Gebbia V, Kraft AS, Pettit GR, Sensenbrenner LL: Antineoplastic bryostatins are multipotent stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci (USA) 84: 8483-8487, 1987
132. Jones R, Sharkis S, Miller C, Rowinsky E, Burke P, May WS: Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood 75: 1319-1323, 1990
133. Kraft AS, William F, Pettit GR, Lilly MB: Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 49: 1287-1293, 1989
134. Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR: Effect of a combined exposure to ara-C, bryostatin 1, and rGM-CSF on the in vitro clonogenic growth of normal and leukemic human hematopoietic progenitor cells. Leukemia 5: 432-439, 1992
135. Hu Z-B, Gignac SM, Uphoff CC, Quentmeier H, Steube KG, Drexler HG: Induction of differentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1. Leuk Lymphoma 10: 135-142, 1993
136. Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammad RM, Al-Katib A: The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-cancer Drugs 6: 392-397, 1995
137. Al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL: Bryostatin 1 modulation of the acute lymphoblastic leukemia cell line Reh. J Immunother 14: 33-42, 1993
138. Al-Katib A, Mohammad RM, Dan M, Hussein ME, Akhtar A: Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 21: 61-65, 1993
139. Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of bryostatin 1 as an anti-cancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52: 101-107, 1992
140. Jarvis WD, Gewirtz D, Povirk L, Turner A, Traylor R, Pettit GR, Grant S: Effect of bryostatin 1 and other activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochemical Pharmacology 47: 839-852, 1994
141. Wang S, Vrana JA, Bartimole T, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S: Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2. Mol Pharmacol 52: 1000-1009, 1997
142. Wang S, Guo Y, Castillo T, Dent P, Grant S: Potentiation of taxol-induced apoptosis and anti-proliferative effects in human myeloid leukemia cells (U937) by bryostatin 1. Biochem Pharmacol 56: 635-644, 1998
143. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL: Successful treatment of Waldenstrom's macroglobulinemia with combination of biological and chemotherapy agents. Cancer Res 54: 165-168, 1994
144. Mohammad RM, Diwarkaran H, Maki A, Emara MA, Pettit GR, Redman B, Al-Katib A: Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 668-673, 1995
145. Mohammad RM, Katato K, Almatchy VP, Wall N, Liu K, Schultz CP, Mantsch HH, Varterasian M, Al-Katib AM: Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by chlorodeoxyadenosine: preclinical studies. Clin Cancer Res 4: 445-453, 1998
146. Bear HD, McFadden A, Turner A, Grant S: Bryostatin 1 induces long-term depletion of protein kinase C in vivo following a single intravenous administration. Anti-Cancer Drugs 6: 384-391, 1995
147. Haldar S, Chintapalli J, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1996
148. Jarvis WD, Fornari FA, Tombes RM, Martin HA, Erkulla RK, Bittman R, Schwartz GK, Dent P, Grant S: Evidence for involvement of MAPK, rather than SAPK, in potentiation of 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis by interruption of the PKC pathway. Mol Pharmacol 54: 844-856, 1998
149. Philip P, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL: Phase I study of bryostatin 1: assessment of interleukin-6 and tumour necrosis factor-α in vivo. J Natl Cancer Inst 85: 1812-1818, 1993
150. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Stern P, McDermott R, Potter M, Pettit GR: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418-424, 1993
151. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR: A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72: 461-468, 1995
152. Scheid C, Prendiville J, Jayson G, Crowther DB, Fox B, Pettit GR, Stern PL: Immunomodulation in patients receiving bryostatin 1 in a phase I clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Chemother Immunother 39: 223-230, 1994
153. Grant S, Roberts J, Bear HD, Poplin E, Tombes M, Kyle B: Phase Ib pharmacodynamic trial of bryostatin 1 in patients with advanced malignancies. Clin Cancer Res 4: 611-618, 1998
154. Vartersian ML, Mohammad RM, Eilander DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BDM, Al-Katib A: Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56-62, 1998
155. Carr ME, Carr SL, Grant S: A sensitive platelet activation-based functional assay for the anti-leukemic agent bryostatin 1. Anti-Cancer Drugs 6: 1-8, 1995
156. Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS: Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56: 802-808, 1996
157. Xia Z, Dickens M, Raingeaud J, David RJ, Greenberg ME: Opposing effects of ERK, JNK, and RK kinases on apoptosis. Science 270: 1326-1331, 1995
158. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S: The roles of signaling by the p42-ERK1/p44-ERK2 mitogen-activated protein kinase (MAPK) pathway: a potential route to radiosensitization and chemosensitization in leukemic cells. Leukemia 12: 1843-1850, 1998
159. Brach MA, Kharbanda SM, Herrmann E, Kufe DW: Activation of the transcription factor κE in human myeloid leukemia cells treated with 1-[β-D-arabinofuranosyl]cytosine. Mol Pharmacol 41: 60-63, 1992
160. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD-098059 is a specific inhibitor of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995
161. Dudley DT, Pang I, Decker SJ, Brifges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci (USA) 92: 7686-7689, 1995
162. Wang S, Wang Z, Boise L, Dent P, Grant S: Loss of the BCL-2 phosphorylation loop increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 259: 67-72, 1999
163. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitti WJ, Earl RA, Hobbs F, Copeland RA, Nagolda RL, Soliere PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998
164. Wang CY, Cusack JC, Liu R, Baldwin AS: Control of indicible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NFκB. Nat Med 5: 412-417, 1999